Identifying new biomarkers to predict cardiovascular events

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to collect biological samples from patients at the Centre for Screening and Prevention of Atherosclerosis at Toulouse University Hospital. The primary goal is to validate new biomarkers that can predict future cardiovascular events, addressing the limitations of existing risk factors. Patients will undergo a comprehensive evaluation, including interviews about lifestyle and clinical examinations, alongside blood sample collection for further analysis. The study also seeks to explore genetic polymorphisms that may influence susceptibility to atherosclerotic diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults over 18 yrs;
* consulting the Centre for Screening and Prevention of Atherosclerosis (CDPA) for management of their cardiovascular risk factors;
* patients on primary prevention, free of personal history of coronary artery disease, stroke or lower limb arteriopathy, or patients on secondary prevention having presented one of the above mentioned diseases;
* patients affiliated to a health insurance system;
* patients having given their written informed consent for a participation to the study and for possible genetic analysis of their personal traits.

Exclusion Criteria:

* Patients under the age of 18;
* patients being under legal protection

Where it's running

• University Hospital Toulouse
  Toulouse, France Recruiting

Study contacts

• Principal investigator: Jean Ferrieres, MD PhD — University Hospital, Toulouse
• Study coordinator: Jean Ferrières, MD PhD
• Email: ferrieres.j@chu-toulouse.fr
• Phone: 562323728

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• One-stop photon-counting CT for patients after PCI

  This study tests a single CT exam using photon-counting technology to image the heart after stent placement in people who have had PCI.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07763340

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.